New heart attack treatment aims to calm dangerous inflammation
NCT ID NCT03515304
Summary
This study tested if adding a cholesterol-lowering drug called evolocumab to standard care could help patients who recently had a specific type of heart attack (NSTEMI). Researchers wanted to see if the drug could further reduce 'bad' cholesterol and, importantly, lower inflammation in the heart and blood vessels. They measured these effects using blood tests and special heart scans in 60 participants over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Steven Paul Schulman
Baltimore, Maryland, 21136, United States
Conditions
Explore the condition pages connected to this study.